课题基金 / 基金详情

RPMS1 circular RNAs in EBV malignancies

RPMS1 circular RNAs in EBV malignancies
EBV 恶性肿瘤中的 RPMS1 环状 RNA
批准号:
10612751
负责人:
ERIK K FLEMINGTON
金额:
$35.86万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-06-01 至 2024-05-31
关键词:
AIDS-Related LymphomaAddressAnimal ModelAutomobile DrivingBiologyCancer EtiologyCancer PatientCarcinomaCell Cycle ProgressionCell DeathCell LineCell ProliferationCellsCellular StressCharacteristicsChromatinCommunitiesDNA Polymerase IIDataDetectionDevelopmentDiseaseEBV-associated diseaseEnvironmentEpstein Barr Virus associated tumorEpstein-Barr Virus InfectionsEpstein-Barr Virus latencyEpstein-Barr Virus-Related Malignant NeoplasmEtiologyGene ExpressionGene Expression RegulationGenesGenetic TranscriptionGoalsGrowthHIVHealthHerpesviridaeHodgkin DiseaseHumanHuman Herpesvirus 4Human Herpesvirus 8ImmuneImmune EvasionImmunologic SurveillanceIn VitroIncidenceInfectionInhibition of ApoptosisIntronsInvestigationLinkLymphocryptovirusLymphomaLyticMaintenanceMalignant NeoplasmsMediatingMicroRNAsModelingMoldsMuridaeNasopharynx CarcinomaNon-Hodgkin&aposs LymphomaOncogenicOncogenic VirusesOverlapping GenesPathway interactionsPatientsPenetrancePhasePhenotypePlayPoly APolyadenylationPoriferaProcessProtein IsoformsProteinsRNARNA SplicingRegulationResearchRhesusRoleS phaseSamplingSignal TransductionSpecimenTimeTranscriptUntranslated RNAViralViral GenesViral ProteinsVirusVirus DiseasesVirus LatencyVirus ReplicationWorkadaptive immune responsecancer cellcell growthcell growth regulationcell typecircular RNAgammaherpesvirusimmune clearancein vivolatent gene expressionmalignant stomach neoplasmnew therapeutic targetpreventprogramspromoterresponsetherapeutic candidatetherapeutic targettranscriptometumortumor growthtumorigenesis

项目摘要

项目成果

ERIK K FLEMINGTON的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Summary EBV is a human tumor virus that is an etiological agent in Hodgkin's lymphoma, non-Hodgkin's lymphomas, stomach cancer and nasopharygeal carcinoma, and it is associated with an increased incidence of lymphomas in the HIV-infected patient context. EBV contributes to oncogenic progression through the expression of one or more viral genes that activate oncogenic pathways along the progression of stages that lead to cancer. A unique aspect of herpesviruses is their utilization of “latency” gene expression programs where no virus replication occurs and only a small subset of viral genes is expressed that remodels the host cell environment to facilitate viral maintenance and persistence. With some of the pathways altered by latency genes overlapping with pathway alterations required for oncogenesis, EBV latency genes are key contributors to the tumor phenotype. Because non-coding RNAs do not elicit adaptive immune responses, the utilization of viral non-coding RNAs in latency settings is a key herpesviral strategy to sustain viral persistence in vivo without promoting immune clearance. We have discovered that EBV expresses a class of largely non-coding RNAs referred to as circular RNAs (circRNAs). Some of these circRNAs are expressed uniquely during reactivation or in distinct latency types where they likely play roles in the corresponding stages of the EBV infection cascade. By assessing viral circRNA expression across a broad range of cell types, latency types, reactivation, in vitro and in patient tumor samples, we have identified a small subset of EBV circRNAs that likely play fundamental roles in EBV biology EBV associated cancers. By performing a circRNAome analysis of the interspecies relative of EBV, the rhesus lymphocryptovirus, we found two of these to be evolutionarily conserved, indicating evolutionary constraints on maintaining their function. In this application, we will analyze the ubiquitiously expressed and conserved EBV circRNA, circRPMS1_E4_E3a. Our preliminary studies show that inhibition of circRPMS1_E4_E3a leads to decreased cell proliferation, indicating a fundamental phenotype in promoting cell growth. In this proposal, we propose three well integrated aims that will assess the fundamental mechanisms of circRPMS1_E4_E3a's interaction with chromatin and regulation of gene expression (aim 1), the influence of these interactions on modulating cell signaling (aim 2), and the link between its cell signaling responses and cell growth control (aim 3).
期刊论文(7)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1038/s41389-021-00373-4
发表时间: 2021-11-29
期刊: Oncogenesis
影响因子: 6.2
作者: [Iftikhar R, Penrose HM, King AN, Samudre JS, Collins ME, Hartono AB, Lee SB, Lau F, Baddoo M, Flemington EF, Crawford SE, Savkovic SD]
通讯作者: Savkovic SD
DOI: 10.3390/metabo12030250
发表时间: 2022-03-16
期刊: Metabolites
影响因子: 4.1
作者: [Iftikhar R, Penrose HM, King AN, Kim Y, Ruiz E, Kandil E, Machado HL, Savkovic SD]
通讯作者: Savkovic SD
DOI: 10.1038/s41417-020-00262-9
发表时间: 2021-09
期刊: Cancer gene therapy
影响因子: 6.4
作者: [Vukadin L, Kim JH, Park EY, Stone JK, Ungerleider N, Baddoo MC, Kong HK, Richard A, Tran J, Giannini H, Flemington EK, Lim SS, Ahn EE]
通讯作者: Ahn EE
DOI: 10.1038/s41598-021-88489-w
发表时间: 2021-04-27
期刊: Scientific reports
影响因子: 4.6
作者: [Penrose HM, Iftikhar R, Collins ME, Toraih E, Ruiz E, Ungerleider N, Nakhoul H, Flemington EF, Kandil E, Shah SB, Savkovic SD]
通讯作者: Savkovic SD
EBV reactivation causes widespread host de novo promoter transcription and transcriptional interference
  • 批准号:
    10647826
  • 项目类别:
  • 资助金额:
    $41.28万
  • 财政年份:
    2022
  • 负责人:
    ERIK K FLEMINGTON
  • 依托单位:
EBV reactivation causes widespread host de novo promoter transcription and transcriptional interference
  • 批准号:
    10548370
  • 项目类别:
  • 资助金额:
    $42.13万
  • 财政年份:
    2022
  • 负责人:
    ERIK K FLEMINGTON
  • 依托单位:
Programmed splicing derangement as new EBV host cell shut-off mechanism
  • 批准号:
    10580068
  • 项目类别:
  • 资助金额:
    $41.79万
  • 财政年份:
    2022
  • 负责人:
    ERIK K FLEMINGTON
  • 依托单位:
Programmed splicing derangement as new EBV host cell shut-off mechanism
  • 批准号:
    10446536
  • 项目类别:
  • 资助金额:
    $42.65万
  • 财政年份:
    2022
  • 负责人:
    ERIK K FLEMINGTON
  • 依托单位:
海外基金